Highlights Approximately one in five patients with MS do not have the disease. The central vein differentiates multiple sclerosis from other white matter lesions. The central vein sign has not been evaluated in multi-center prospective studies. CAVS-MS is a prospective multicenter study to validate the central vein. CAVS-MS will useT2*-weighted, high-isotropic-resolution, segmented echo-planar MRI.

Considerations regarding clinical effectiveness and cost are essential in comparing the overall value of two treatments. There has been growing interest in methodology to integrate cost and effectiveness measures in order to inform policy and promote adequate resource allocation. The net monetary benefit aggregates information on differences in mean cost and clinical outcomes; the cost-effectiveness acceptability curve was developed to characterize the extent to which the strength of evidence regarding net monetary benefit changes with fluctuations in the willingness-to-pay threshold. Methods to derive insights from characteristics of the cost/clinical outcomes besides mean differences remain undeveloped but may also be informative. We propose a novel probabilistic measure of cost-effectiveness based on the stochastic ordering of the individual net benefit distribution under each treatment. Our approach is able to accommodate features frequently encountered in observational data including confounding and censoring, and complements the net monetary benefit in the insights it provides. We conduct a range of simulations to evaluate finite-sample performance and illustrate our proposed approach using simulated data based on a study of endometrial cancer patients.

IMPORTANCE Increasing demand for cancer care may be outpacing the capacity of hospitals to provide timely treatment, particularly at referral centers such as National Cancer Institute (NCI)designated and academic centers. Whether the rate of patient volume growth has strained hospital capacity to provide timely treatment is unknown.OBJECTIVE To evaluate trends in patient volume by hospital type and the association between a hospital's annual patient volume growth and time to treatment initiation (TTI) for patients with cancer.

To make informed policy recommendations from observational panel data, researchers must consider the effects of confounding and temporal variability in outcome variables. Difference-in-Difference methods allow for estimation of treatment effects under the parallel trends assumption. To justify this assumption, methods for matching based on covariates, outcome levels, and outcome trends-such as the synthetic control approach-have been proposed. While these tools can reduce bias and variability in some settings, we show that certain applications can introduce regression to the mean (RTM) bias into estimates of the treatment effect. Through simulations, we show RTM bias can lead to inflated type I error rates as well as bias towards the null in typical policy evaluation settings. We develop a novel correction for RTM bias that allows for valid inference and show how this correction can be used in a sensitivity analysis. We apply our proposed sensitivity analysis to reanalyze data concerning the effects of California's Proposition 99, a large-scale tobacco control program, on statewide smoking rates.

A key factor in designing randomized clinical trials is the sample size required to achieve a particular level of power to detect the benefit of a treatment. Sample size calculations depend upon the expected benefits of a treatment (effect size), the accuracy of measurement of the primary outcome, and the level of power specified by the investigators. In this study, we show that radiomic models, which leverage complex brain MRI patterns and machine learning, can be utilized in clinical trials with protocols that incorporate baseline MR imaging to significantly increase statistical power to detect treatment effects. Akin to the historical control paradigm, we propose to utilize a radiomic prediction model to generate a pseudo-control sample for each individual in the trial of interest. Because the variability of expected outcome across patients can mask our ability to detect treatment effects, we can increase the power to detect a treatment effect in a clinical trial by reducing that variability through using radiomic predictors as surrogates. We illustrate this method with simulations based on data from two cohorts in different neurologic diseases, Alzheimer’s disease and glioblastoma multiforme. We present sample size requirements across a range of effect sizes using conventional analysis and models that include a radiomic predictor. For our Alzheimer’s disease cohort, at an effect size of 0.35, total sample size requirements for 80% power declined from 246 to 212 for the endpoint cognitive decline. For our glioblastoma multiforme cohort, at an effect size of 1.65 with the endpoint survival time, total sample size requirements declined from 128 to 74. This methodology can decrease the required sample sizes by as much as 50%, depending on the strength of the radiomic predictor. The power of this method grows with increased accuracy of radiomic prediction, and furthermore, this method is most helpful when treatment effect sizes are small. Neuroimaging biomarkers are a powerful and increasingly common suite of tools that are, in many cases, highly predictive of disease outcomes. Here, we explore the possibility of using MRI-based radiomic biomarkers for the purpose of improving statistical power in clinical trials in the contexts of brain cancer and prodromal Alzheimer’s disease. These methods can be applied to a broad range of neurologic diseases using a broad range of predictors of outcome to make clinical trials more efficient.